Patient and Partner Perception After Remission of Cushing's Syndrome

NCT ID: NCT03607474

Last Updated: 2023-05-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-03-30

Study Completion Date

2023-05-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hypercortisolism leads to long term physical and cognitive sequelae. This also holds true for quality of life, even several years after remission. This altered quality of life, highly subjective, is however, badly evaluated by the family of the patient. This could lead to misunderstanding, avec worsen the general physical and mental health of the patient. To our knowledge, this theoretical difference of perception has never been evaluated up to now.

The aim of our study is to evaluate the difference of perception of the quality of life and body image between patients in remission of hypercortisolism, and their caregivers. Secondary objectives will be to evaluate the quality of life of the caregivers, the coping strategies, and the depression/anxiety parameters of both the patient and the caregiver. Patients and methods: the study is Observative, prospective and non-randomized. Inclusion criteria will be patients, aged more than 18, with hypercortisolism in remission for at least 1 year. Self-questionnaires on quality of life, body image, coping, depression and anxiety will be provided to the patient and his/her caregiver. Fulfilling will be blind between the patient and his/her caregiver. Inclusion period will be 12 months.

Results will be compared between the patient and his/her caregiver. Expected results: investigators anticipate that some caregivers will have a different perception of the general physical and mental condition as stated by the patient. The first time that the quality of life of the caregiver would be also altered.

This original project might lead to modify the management of Cushing's syndrome, by considering both the patient and his/her caregiver on a long term basis after remission.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Introduction: Hypercortisolism leads to long term physical and cognitive sequelae. This also holds true for quality of life, even several years after remission. This altered quality of life, highly subjective, is however, badly evaluated by the family of the patient. This could lead to misunderstanding, avec worsen the general physical and mental health of the patient. To our knowledge, this theoretical difference of perception has never been evaluated up to now. Aims: The aim of our study is to evaluate the difference of perception of the quality of life and body image between patients in remission of hypercortisolism, and their caregivers. Secondary objectives will be to evaluate the quality of life of the caregivers, the coping strategies, and the depression/anxiety parameters of both the patient and the caregiver. Patients and methods: the study is Observative, prospective and non-randomized. Inclusion criteria will be patients, aged more than 18, with hypercortisolism in remission for at least 1 year. Self-questionnaires on quality of life, body image, coping, depression and anxiety will be provided to the patient and his/her caregiver. Fulfilling will be blind between the patient and his/her caregiver. Inclusion period will be 12 months. Results will be compared between the patient and his/her caregiver. Expected results: investigators anticipate that some caregivers will have a different perception of the general physical and mental condition as stated by the patient. The first time that the quality of life of the caregiver could be also altered. Perspectives: This original project might lead to modify the management of Cushing's syndrome, by considering both the patient and his/her caregiver on a long term basis after remission.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypercorticism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Couple (Patients and caregivers)

Patient in remission of hypercortisolism Caregivers will be the spouse or, failing that, a person close to the patient, who has been in regular contact with the patient since taking care of him.

Questionnaires of life quality for patients Questionnaires of life quality for caregivers

Questionnaires of life quality for patients

Intervention Type OTHER

* the WhoQoL
* a specific scale of Cushing's syndrome
* The Beck II scale
* HAD scale
* Rosenberg questionnaire
* Stunkard, Sorensen and Schlusinger (1983) figurines
* Brief Cope scale

Questionnaires of life quality for caregivers

Intervention Type OTHER

* the WhoQoL
* The Beck II scale
* HAD scale

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Questionnaires of life quality for patients

* the WhoQoL
* a specific scale of Cushing's syndrome
* The Beck II scale
* HAD scale
* Rosenberg questionnaire
* Stunkard, Sorensen and Schlusinger (1983) figurines
* Brief Cope scale

Intervention Type OTHER

Questionnaires of life quality for caregivers

* the WhoQoL
* The Beck II scale
* HAD scale

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject, male or female over 18
* Subject presenting a hypercortisolism in remission or controlled by a drug treatment for more than one year.
* Subject with a good understanding of the French language
* Non-institutionalized subject
* Subject whose informed consent could be obtained

Exclusion Criteria

* Minor subject or over 80 years
* Subject presenting hypercortisolism in remission for more than 20 years
* Major cognitive impairment that does not allow answering a questionnaire
* Genetic syndrome responsible for hypercortisolism
* Mixed adenoma whose corticotropic share is responsible for hypercortisolism
* Pituitary carcinoma
* Subject refusing to participate in the study
* Subject having no close
* Subject whose relative refuses to answer the questionnaires
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assistance Publique Hopitaux De Marseille

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

EMILIE GARRIDO PRADALIE

Role: STUDY_DIRECTOR

APHM DRIC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Assistance Publique Des Hopitaux de Marseille

Marseille, PACA, France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2018-38

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Stress Hormones and IUDs
NCT03499379 COMPLETED